These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 18508374)
41. Cellular immune function monitoring after allogeneic haematopoietic cell transplantation: evaluation of a new assay. Israeli M; Klein T; Herscovici C; Ram R; Shpilberg O; Sredni B; Yeshurun M Clin Exp Immunol; 2013 Jun; 172(3):475-82. PubMed ID: 23600836 [TBL] [Abstract][Full Text] [Related]
42. Can immune function assay predict infection or recovery? Moon HH; Kim TS; Roh YN; Lee S; Song S; Shin M; Kim JM; Hyuck C; Kwon D; Kim SJ; Joh JW; Lee SK Transplant Proc; 2012 May; 44(4):1048-51. PubMed ID: 22564622 [TBL] [Abstract][Full Text] [Related]
43. Clinical relevance of immune monitoring in solid organ transplantation. Daniel V; Opelz G Int Rev Immunol; 2009; 28(3-4):155-84. PubMed ID: 19811320 [TBL] [Abstract][Full Text] [Related]
44. Immune functional assay for immunosuppressive management in post-transplant malignancy. Uemura T; Riley TR; Khan A; Hollenbeak C; Schreibman I; Ghahramani N; Reeves B; Domen RE; Zander DS; Kadry Z Clin Transplant; 2011; 25(1):E32-7. PubMed ID: 20636411 [TBL] [Abstract][Full Text] [Related]
45. Lack of association of immune cell function test with rejection in kidney transplantation. Torío A; Fernández EJ; Montes-Ares O; Guerra RM; Pérez MA; Checa MD Transplant Proc; 2011; 43(6):2168-70. PubMed ID: 21839223 [TBL] [Abstract][Full Text] [Related]
46. Use of split-liver allografts does not impair pediatric recipient growth. Mejia A; Barshes N; Halff G; Goss J; Washburn WK Liver Transpl; 2007 Jan; 13(1):145-8. PubMed ID: 17029283 [TBL] [Abstract][Full Text] [Related]
47. Screening of mortality in transplant patients using an assay for immune function. Berglund D; Bengtsson M; Biglarnia A; Berglund E; Yamamoto S; von Zur-Mühlen B; Lorant T; Tufveson G Transpl Immunol; 2011 May; 24(4):246-50. PubMed ID: 21232600 [TBL] [Abstract][Full Text] [Related]
55. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150 [TBL] [Abstract][Full Text] [Related]
56. Humoral and cellular immune monitoring might be useful to identify liver transplant recipients at risk for development of infection. Carbone J; Micheloud D; Salcedo M; Rincon D; Bañares R; Clemente G; Jensen J; Sarmiento E; Rodriguez-Molina J; Fernandez-Cruz E Transpl Infect Dis; 2008 Dec; 10(6):396-402. PubMed ID: 18657086 [TBL] [Abstract][Full Text] [Related]
57. Analysis of CD8+CD28- T-suppressor cells in living donor liver transplant recipients. Lin YX; Wang LL; Yan LN; Cai P; Li B; Wen TF; Zeng Y Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):241-6. PubMed ID: 19502162 [TBL] [Abstract][Full Text] [Related]
58. Association of mast cells and liver allograft rejection. Arikan C; Nart D; Kilic M; Yuksekkaya HA; Aydogdu S Pediatr Transplant; 2008 May; 12(3):347-52. PubMed ID: 18435610 [TBL] [Abstract][Full Text] [Related]
60. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients. Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]